Arrhythmias & electrophysiology
Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib
Authors' conclusion
IBR increases the risk of SCD among patients with cardiac risk factors. Stress and ambulatory electrocardiogram on IBR identified asymptomatic arrhythmias altering clinical management in 19% of patients.
Study context
- Population
- Patients with chronic lymphocytic leukemia treated with ibrutinib (IBR)21 asymptomatic in cross-sectional analysis
- Participants
- 131 patients
- Outcome
- Incidence of SCD and asymptomatic arrhythmias on IBR
Main finding
As reported in the abstract
SCD incidence on IBR · median 66.5 months on IBR
Sudden cardiac death (SCD) cases
5
SCD incidence per 100,000 patient-years
801
vs general population
≈2-4× higher
Observational data: associations, not effects.
Further findings
Previously unknown clinically significant arrhythmias in asymptomatic patients (cross-sectional analysis)
- Patients with arrhythmias
- 4 (19%)
- Precautionary IBR discontinuation
- 2
- n = 21 asymptomatic patients
Characteristics of SCD cases
- Autopsies performed (of 5 SCD); no acute pathologic process, evolving cardiac pathology
- 3
- All SCD patients had ≥1 cardiac risk factor
Original publication
Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib. Heart Rhythm. Published 10 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →